$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

$plrx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000174647324000076 Filed on May 06, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.02M	$15.25M
YoY Change	3.07%	7.72%
% of Gross Profit
Research & Development	$45.62M	$37.15M
YoY Change	38.22%	26.9%
% of Gross Profit
Depreciation & Amortization	$600.0K	$500.0K
YoY Change	25.79%	0.0%
% of Gross Profit
Operating Expenses	$60.64M	$52.39M
YoY Change	27.46%	20.64%
Operating Profit	-$60.64M	-$52.39M
YoY Change	28.13%	24.46%
Interest Expense	$4.785M	$445.0K
YoY Change	1400.0%	43.09%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$55.85M	-$46.96M
YoY Change	35.59%	25.05%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$55.85M	-$46.96M
YoY Change	35.59%	25.05%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.92	-$0.78
Diluted Earnings Per Share	-$0.92	-$0.78
COMMON SHARES
Basic Shares Outstanding	60.33M shares	60.24M shares
Diluted Shares Outstanding	60.38M shares	60.18M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$436.6M	$482.4M
YoY Change	-21.35%	-16.44%
Cash & Equivalents	$80.39M	$114.3M
Short-Term Investments	$356.2M	$368.1M
Other Short-Term Assets	$8.143M	$5.194M
YoY Change	24.89%	-15.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$447.6M	$489.9M
YoY Change	-20.89%	-16.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.395M	$5.605M
YoY Change	-36.66%	33.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$437.0K	$392.0K
YoY Change	-34.97%	-39.13%
Total Long-Term Assets	$36.18M	$31.71M
YoY Change	293.66%	228.43%
TOTAL ASSETS
Total Short-Term Assets	$447.6M	$489.9M
Total Long-Term Assets	$36.18M	$31.71M
Total Assets	$483.7M	$521.6M
YoY Change	-15.86%	-12.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.247M	$7.327M
YoY Change	40.56%	416.35%
Accrued Expenses	$8.196M	$5.868M
YoY Change	-69.88%	-73.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$30.92M	$30.39M
YoY Change	4.76%	31.26%
LONG-TERM LIABILITIES
Long-Term Debt	$30.07M	$30.00M
YoY Change	201.06%	201.29%
Other Long-Term Liabilities	$30.06M	$23.88M
YoY Change	1196.72%	737.89%
Total Long-Term Liabilities	$60.13M	$53.88M
YoY Change	388.61%	320.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.92M	$30.39M
Total Long-Term Liabilities	$60.13M	$53.88M
Total Liabilities	$91.05M	$84.27M
YoY Change	117.69%	134.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$602.6M	-$546.7M
YoY Change	44.45%	45.42%
Common Stock	$995.9M	$984.5M
YoY Change	4.56%	4.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$392.7M	$437.3M
YoY Change
Total Liabilities & Shareholders Equity	$483.7M	$521.6M
YoY Change	-15.86%	-12.76%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$55.85M	-$46.96M
YoY Change	35.59%	25.05%
Depreciation, Depletion And Amortization	$600.0K	$500.0K
YoY Change	25.79%	0.0%
Cash From Operating Activities	-$45.30M	-$30.27M
YoY Change	82.95%	-0.02%
INVESTING ACTIVITIES
Capital Expenditures	$1.251M	$1.492M
YoY Change	107.46%	815.34%
Acquisitions
YoY Change
Other Investing Activities	$11.95M	$61.04M
YoY Change	-153.42%	-135.07%
Cash From Investing Activities	$10.70M	$59.55M
YoY Change	-146.57%	-134.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	684.0K	$21.79M
YoY Change	324.84%	-92.03%
NET CHANGE
Cash From Operating Activities	-45.30M	-$30.27M
Cash From Investing Activities	10.70M	$59.55M
Cash From Financing Activities	684.0K	$21.79M
Net Change In Cash	-33.91M	$51.06M
YoY Change	-28.72%	-25.83%
FREE CASH FLOW
Cash From Operating Activities	-$45.30M	-$30.27M
Capital Expenditures	$1.251M	$1.492M
Free Cash Flow	-$46.55M	-$31.76M
YoY Change	83.53%	4.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-52392000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-42095000	usd
CY2024Q1	plrx	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	5882000	usd
CY2023Q1	plrx	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	4858000	usd
CY2024Q1	plrx	Number Of Votes Per Share Of Common Stock NumberOfVotesPerShareOfCommonStock	1	vote
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37146000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29273000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15246000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14154000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	52392000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	43427000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	445000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	311000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-46955000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60180921	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60180921	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56057603	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56057603	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-46955000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-834000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	627000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-834000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	627000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47789000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36921000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	473576000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1879000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9666000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-834000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	437332000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	313342000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	269915000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	3661000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11923000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	627000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	561920000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	513000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	452000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9666000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11923000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	681000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	609000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1091000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2584000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1314000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3749000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	476000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2257000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-144000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-910000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-538000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-363000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-656000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30271000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30276000	usd
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	52375000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	276620000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	113413000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	102575000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1492000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	163000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59546000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-174208000	usd
CY2024Q1	plrx	Proceeds From Issuances Of Common Stock Under Benefit Plans ProceedsFromIssuancesOfCommonStockUnderBenefitPlans	1879000	usd
CY2023Q1	plrx	Proceeds From Issuances Of Common Stock Under Benefit Plans ProceedsFromIssuancesOfCommonStockUnderBenefitPlans	3661000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	19909000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2024Q1	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	0	usd
CY2023Q1	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	586000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	270251000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21788000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	273326000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	51063000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	68842000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64716000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33685000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115779000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102527000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	501000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	282000	usd
CY2024Q1	plrx	Cash And Cash Equivalents At Carrying Value Rounded CashAndCashEquivalentsAtCarryingValueRounded	114297000	usd
CY2023Q1	plrx	Cash And Cash Equivalents At Carrying Value Rounded CashAndCashEquivalentsAtCarryingValueRounded	102527000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	1482000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115779000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102527000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-834000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	636000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1059000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23698000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, stock-based compensation expense, operating lease right-of-use (“ROU”) assets and liabilities, accruals and prepayments for research and development costs, income taxes and uncertain tax positions. The Company assesses estimates on an ongoing basis, however, actual results could materially differ from those estimates.</span></div>
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	451913000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	150000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	640000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	451423000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	487907000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	822000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	477000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	488252000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	451913000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	150000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	640000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	451423000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	487907000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	822000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	477000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	488252000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14800000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14800000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12249000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9195000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9195000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8682000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5605000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5605000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3567000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	500000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	500000	usd
CY2024Q1	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	2540000	usd
CY2023Q4	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	3403000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	769000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1131000	usd
CY2024Q1	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	1274000	usd
CY2023Q4	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	2454000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	2315000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2997000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	611000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1272000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7509000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11257000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4541000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9042000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1327000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1177000	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5868000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10219000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	10000000	usd
CY2024Q1	plrx	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	0	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	30000000	usd
CY2024Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	191000	usd
CY2024Q1	plrx	Long Term Debt Accretion Of Final Payment LongTermDebtAccretionOfFinalPayment	193000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	30002000	usd
CY2024Q1	plrx	Number Of Classes Of Stock Authorized NumberOfClassesOfStockAuthorized	2	class
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15742708	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12544982	shares
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9666000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11923000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	plrx	Valuation Allowance As Percentage On Deferred Tax Assets ValuationAllowanceAsPercentageOnDeferredTaxAssets	1
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q1	plrx	Contractual Arrangements Cancellation Period ContractualArrangementsCancellationPeriod	P30D
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2037000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2849000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3537000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4735000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5996000	usd
CY2024Q1	plrx	Lessee Operating Lease Liability To Be Paid Year Four And After Year Four LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfterYearFour	16718000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	35872000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11219000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	773000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23880000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.082
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	972000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	770000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	165000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	243000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	1137000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	1013000	usd
CY2024Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8861584	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7549127	shares
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001746473-24-000076-index-headers.html	Edgar Link	pending
0001746473-24-000076-index.html	Edgar Link	pending
0001746473-24-000076.txt	Edgar Link	pending
0001746473-24-000076-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plrx-20240331.htm	Edgar Link	pending
plrx-20240331.xsd	Edgar Link	pending
plrx-20240331xex311.htm	Edgar Link	pending
plrx-20240331xex312.htm	Edgar Link	pending
plrx-20240331xex321.htm	Edgar Link	pending
plrxrestatedloanagreement-.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
plrx-20240331_cal.xml	Edgar Link	unprocessable
plrx-20240331_def.xml	Edgar Link	unprocessable
plrx-20240331_pre.xml	Edgar Link	unprocessable
plrx-20240331_lab.xml	Edgar Link	unprocessable
plrx-20240331_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

2024 Q2 Form 10-Q Financial Statement

#000174647324000076 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX PLIANT THERAPEUTICS, INC. Stock $plrx

2024 Q2 Form 10-Q Financial Statement

#000174647324000076 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx